Whitepaper: CDMOs at a Crossroads
The contract development and manufacturing organization (CDMO) sector is undergoing a rapid transformation as pharma and biotech firms chase end‑to‑end solutions for biologics, cell and gene therapies. Demand for specialized partnerships is rising alongside U.S. policies that encourage domestic production. AI, automation, and evolving FDA guidance are reshaping service offerings beyond pure capacity. The whitepaper highlights these forces and invites stakeholders to download the full analysis.
BMS Makes a Beeline, Bringing 5 Assets to Biotech's $300M Precision Immunology Debut
Bristol Myers Squibb has spun out a new biotech, Beeline Medicines, backed by $300 million from Bain Capital and an initial portfolio of five assets. The company, led by former SpringWorks CEO Saqib Islam, will focus on precision therapies for autoimmune...
Takeda Continues to Prune Partnerships, Cuts Ties with mRNA-Targeting Veritas In Silico
Takeda announced the termination of its three‑year partnership with Veritas In Silico, a collaboration focused on small‑molecule drugs that target mRNA. The split, confirmed on April 13, follows a recent wave of collaborator cuts, including a break with Denali Therapeutics and...
J&J Targets $100B Revenue, Replimune Rebuffed Again and a “Revolution” In Pancreatic Cancer
Johnson & Johnson reported $24.1 billion in first‑quarter sales and set an ambitious $100 billion revenue target for 2026, underscoring its aggressive growth strategy amid a wave of biotech M&A. Replimune’s advanced melanoma therapy RP1 was denied again, with the FDA insisting...
Could Biotech Layoffs Push Life Sciences Talent to Go Global?
Biotech firms are trimming staff amid a funding slowdown, but the layoffs are prompting a global reshuffling of life‑sciences talent. Major U.S. hubs like Boston see cuts, while the UK, Canada, France, Switzerland and Singapore roll out visa pathways and...
5 Biopharma M&A Deals Where the Workforce Was the Prize
Recent biopharma mergers highlight that talent can be as valuable as assets. Gilead’s $5 billion purchase of Tubulis, Biogen’s $5.6 billion acquisition of Apellis, and AstraZeneca’s $2.4 billion buy of Fusion all emphasize acquiring specialized teams. Other deals, such as AstraZeneca’s $1.06 billion Amolyt...
Deep Dive: Checking in with the FDA
The FDA’s 2025 turmoil included a 3,500‑person workforce cut, multiple leadership turnovers, and a surge in guidance reversals that delayed drug reviews. In 2026, the agency declined to file Moderna’s mRNA‑1010 flu vaccine, contradicting earlier guidance, underscoring regulatory uncertainty. Despite...
FDA Bolsters Bespoke Therapy Framework with New Draft Safety Guidelines
The FDA’s Center for Biologics Evaluation and Research issued draft guidance to standardize safety assessments for genome‑editing therapies, covering both ex vivo and in vivo products that use next‑generation sequencing to detect off‑target effects. The recommendations target nonclinical studies supporting IND and...
50 Employees Impacted as Astellas Closes Universal Cells' Seattle Office
Tokyo‑based Astellas Pharma announced the closure of Universal Cells' Seattle office, affecting 50 employees. A handful of staff will be transferred to Astellas’ research sites in South San Francisco and Westborough, while the remainder face layoffs in waves from July...
Bonus: Q1 2026 Job Market Update
BioSpace’s Vice President of Marketing Chantal Dresner and Careers Editor Angela Gabriel released a bonus podcast analyzing Q1 2026 job‑market performance in the life‑sciences sector. Their discussion highlights a noticeable dip in layoffs across biotech, pharma and med‑tech firms between January...
Lilly Investing Billions to Prepare for Overseas Oral GLP-1 Launches
Eli Lilly announced a $3 billion investment in China and a $125 million spend in Japan to build capacity for its newly approved oral GLP‑1 drug, orforglipron. The moves aim to localize production, shorten lead times and hedge against geopolitical disruptions. Analysts see...
Lilly Wants to Bridge Cancer Care Gap with $300M ADC Biotech Buy
Eli Lilly announced an acquisition of Houston‑based CrossBridge Bio, offering up to $300 million in cash and performance‑based biobucks. The early‑stage biotech is developing a dual‑payload antibody‑drug conjugate, CBB‑120, that targets the TROP2 protein found in many solid tumors. CrossBridge plans to...
Kailera Eyes Record $533M+ IPO to Play in Competitive Obesity Space with Chinese Drugs
Kailera Therapeutics announced an IPO that could raise up to $610 million, potentially the largest biotech debut in years. The company will sell 33 million shares at $14‑$16 each, with an underwriter option for an additional 5 million shares. Proceeds will augment a...
USP Adds Tamiflu, Trulicity to Vulnerable List as Upstream Analysis Reshapes Supply Concerns
The United States Pharmacopeia (USP) has refreshed its vulnerable medicines list, adding Tamiflu (oseltamivir) and Trulicity (dulaglutide) after expanding its risk assessment to include key starting materials (KSMs). The new analysis shows 48 of the 100 flagged drugs depend on...
Allogene Stock Sails After CAR T Clears Residual Lymphoma in Early Data Cut
Allogene Therapeutics reported interim results from its Phase 2 ALPHA3 trial showing its off‑the‑shelf CAR‑T product cema‑cel cleared measurable residual disease in 58.3% of patients versus 16.7% in the observation arm. The therapy also achieved a 97.7% drop in circulating tumor...
Revolution Rises 40% as Pancreatic Cancer Drug Doubles Survival
Revolution Medicines announced that its oral RAS inhibitor daraxonrasib doubled overall survival in patients with previously treated metastatic pancreatic ductal adenocarcinoma, achieving 13.2 months versus 6.7 months on chemotherapy. The Phase 3 RASolute 302 interim analysis was declared final, prompting the company...
Regeneron Enters Radiopharma Ring with up to $4.3B Telix Alliance
Regeneron Pharmaceuticals has struck a partnership with Australian biotech Telix, committing $40 million to launch four initial radiopharmaceutical programs and securing an option for four more. The deal splits development and commercialization costs and profits equally, while Telix stands to earn...
FDA’s CRL Transparency Policy Is Boosting Biopharma Accountability
More than a year after the FDA launched its radical transparency agenda, the agency has released over 200 complete response letters (CRLs) covering 2020‑2024 and added historic letters back to 2002. Public availability forces biotech firms to align their disclosures...
Your Scale, Your Terms: How Modular Bioreactors Are Redefining Capacity & Manufacturing Strategies
AGC Biologics is championing a scale‑out strategy that uses modular single‑use bioreactors instead of traditional stainless‑steel scale‑up. Its proprietary 6Pack System™ links up to six 2,000‑liter disposable reactors, delivering flexible capacities from 2 kL to 12 kL while preserving process parameters. The approach...
Replimune’s Advanced Melanoma Drug Rebuffed by FDA for Second Time
Replimune’s oncolytic immunotherapy RP1, aimed at unresectable advanced cutaneous melanoma, was rejected by the FDA for a second time on April 6, 2026. The agency’s complete response letter said the data, derived from a single‑arm trial, were insufficient to demonstrate substantial effectiveness,...
Opinion: For AI to Have Impact, the Industry Must Align on Data
Artificial intelligence is now embedded across biopharmaceutical R&D, highlighted by the FDA's adoption of the generative tool Elsa for drug‑approval reviews. Industry leaders, including Charles River Laboratories, warn that AI's promise hinges on the quality, metadata, and harmonization of the...
FDA Probes Abortion Pill Anew After Court Keeps Mail Access Alive
The FDA announced a renewed, accelerated safety study of the abortion pill mifepristone, aiming to complete the review faster than typical academic timelines. The move follows a Louisiana federal judge’s decision to temporarily allow the drug’s distribution by mail while...
Avalyn Plots IPO to Push Inhaled Pulmonary Fibrosis Pipeline Through Clinic
Avalyn Pharma announced its intent to launch an IPO on Nasdaq under the ticker AVLN, though the number of shares and target raise remain undisclosed. The company will channel the proceeds into advancing its inhaled pulmonary‑fibrosis pipeline, beginning with AP01,...
Innovent’s CDMO Gets Green Light to Make Biologics at Large Chinese Plant
Innovent Biologics’ CDMO, Altruist Biologics, received its first 20,000‑liter biologics production license from China’s NMPA for the Hangzhou plant, marking the country’s inaugural facility of this scale. The site, equipped with four 20,000‑liter bioreactors, will be expanded to 172,000 liters, complementing...
Automation, Collaboration and the Future of Advanced Therapies
BioSpace’s Denatured podcast episode explores how soaring demand for cell and gene therapies is driving the industry toward automation, digitization, and robotics. Guests Jason Jones of Cellular Origins and Alexander Seyf of Autolomous discuss the need for scalable, sterile manufacturing workflows...
Gilead Less M&A Happy Now but Door Still Open for ‘Compelling’ Opportunities
Gilead Sciences announced a third 2026 acquisition, buying German ADC specialist Tubulis for $5 billion, bringing its total spend on three deals this year to $14.77 billion. The spree began with a $7.59 billion purchase of CAR‑T partner Arcellx and a $2.18 billion deal...
Insmed Scraps Skin Plans for Lung Disease Drug as Competitors Make Headway
Insmed announced it will drop development of its lung‑disease drug Brinsupri for hidradenitis suppurativa after the Phase 2b CEDAR trial showed no efficacy, with placebo outperforming both tested doses. The study also missed secondary endpoints, prompting the company to cease the...
Lilly’s Foundayo Nod Launches New Battle With Novo, M&A Mania Continues, Tariffs Hit Pharma
Eli Lilly received FDA approval for its oral obesity drug Foundayo (orforglipron), sparking a direct rivalry with Novo Nordisk’s Wegovy pill, which posted a modest efficacy edge in Phase 3 trials. The drug’s convenience—no water required—could differentiate it in a crowded market. Meanwhile,...
When a Good Boss Is Bad for Your Career
The piece argues that not all good bosses drive career growth, separating “stretch leaders” who broaden scope and expose employees to senior‑level reasoning from “comfort leaders” who shield teams from politics but limit development. Stretch leaders build judgment, visibility, and...
As CGT Manufacturing Scales Up, Automation and Collaboration Become Essential
Cell and gene therapy manufacturing faces a scalability crunch as single batches cost over $500,000 and skilled labor shortages drive high turnover. Companies are turning to robotics, AI, and digital dashboards to automate processes, cut contamination risk, and harness real‑time...
Daré's CEO Wants Everyone To Invest in Women’s Health, Starting With Her Company
Daré Bioscience, led by CEO Sabrina Martucci Johnson, launched a Regulation A offering to raise $24.3 million, allowing individuals to invest as little as $250. The biotech focuses exclusively on women’s‑health therapeutics, including menopause, fertility, and vaginal‑health products, with its first solo...
AbbVie Puts Humira on TrumpRx at Steep Discount as Tariff Threat Solidifies
AbbVie has agreed to sell its blockbuster arthritis drug Humira on the Trump administration’s direct‑to‑consumer platform TrumpRx for about $950, an 86 % cut from the typical $6,900 out‑of‑pocket price. The deal, announced after AbbVie pledged $100 billion in R&D and manufacturing...
FDA Seeks Expanded Authority To Regulate Postapproval Manufacturing Changes
The FDA is requesting new legislative authority to enforce post‑approval manufacturing changes, including major facility or active pharmaceutical ingredient (API) supplier switches. The proposal, part of the FY 2027 budget, would amend the 1997 FD&C Act to require validation and approval...
FDA’s 2027 Budget Proposes Permanent Rare Disease Vouchers, Easier Entry to Clinic
President Trump’s FY 2027 budget proposes a $7.23 billion allocation for the FDA, a 3.2% increase over 2026, while the broader HHS budget shrinks by 12%. The agency plans to make the rare pediatric disease priority‑review voucher program permanent, averting an estimated...
Pharma Pipeline Stalls for First Time in Decades: Citeline
The Citeline Pharma R&D report shows the first decline in investigational drug candidates since the mid‑1990s, with the pipeline falling 3.92% to 22,940 assets at the start of 2026. While a methodological tweak may have softened the drop, the contraction...
AI Giant Anthropic Leans Into Life Sciences With $400M Coefficient Bio Catch
Anthropic is buying New York‑based biotech startup Coefficient Bio for an estimated $400 million, folding the stealth‑mode firm into its newly created Claude Life Sciences team. Coefficient’s founders bring machine‑learning experience from Roche’s Genentech, bolstering Anthropic’s push into drug‑discovery, clinical‑trial, and...
Takeda Breaks Up With Denali, Dumps Dementia Drug
Takeda Pharmaceutical has ended its eight‑year partnership with Denali Therapeutics, returning all rights to the frontotemporal dementia candidate DNL593. The split follows earlier termination of the joint Alzheimer’s program DNL919 and is attributed to strategic considerations rather than safety or...
FDA Reversals in Rare Disease Space Highlight Confusion Around External Controls
In 2024 the FDA signaled support for using natural‑history external controls in rare‑disease gene‑therapy trials, but later reversed that stance for uniQure’s Huntington’s therapy, demanding a sham‑surgery Phase 3 study. The agency’s guidance still encourages innovative designs, yet recent reversals for...
Lean Derisking: Smart Ways to Cross Drug Development’s “Valley of Death”
API’s recent webinar highlighted practical strategies to bridge the drug‑development "valley of death," emphasizing early derisking from discovery through first‑in‑human studies. The panel stressed using AI‑driven in‑silico filters, staged in‑vitro and animal testing, and aligning preclinical models with clinical biomarkers...
BioNTech Starts Shuttering Singapore mRNA Manufacturing Site Amid Pipeline Pivot
BioNTech announced it will shut its Singapore mRNA manufacturing plant by the end of February 2027, ending a venture that began with a $355 million investment in 2022. The site, originally slated to create over 100 jobs and produce several hundred...
11 Startups Selected for National Life Sciences Accelerator Program
Eleven early‑stage life‑sciences startups were chosen for the Drive accelerator, with eight headquartered in Massachusetts and the remaining three in South Carolina. MassBio will manage the biotech cohort while SCbio leads the biomarkers and diagnostics group. The free eight‑week program...
Biopharma M&A Heats Up, Rare Diseases Win Three Approvals, Wave Crashes
Biopharma giants Biogen, Eli Lilly and Merck collectively spent over $20 billion in a single week to acquire biotech firms with approved products or promising pipelines, accounting for three of the year’s four largest deals. Merck bought Terns Pharmaceuticals for $6.7 billion, while...
Ambrosia Eyes Next-Generation Small Molecule GLP-1s With $100M Series B
Ambrosia Biosciences announced the completion of a $100 million Series B financing round to fund the development of next‑generation small‑molecule GLP‑1 oral therapies for obesity. The capital will support a Phase 1 trial of its lead GLP‑1 candidate, which leverages AI‑driven molecular design...
IO Shuts Down Following Regulatory Roadblocks
Danish biotech IO Biotech announced it will wind down operations and file for Chapter 7 bankruptcy after regulatory setbacks. The FDA rejected its biologics license application for the cancer vaccine Cylembio in September, citing insufficient data. A Phase 3 trial combining Cylembio...
3 Career Moves R&D Professionals Must Make in a Skills-Based, AI-Driven Economy
Biopharma R&D careers are shifting from title‑driven ladders to skills‑centric portfolios as AI automates routine tasks. Professionals must treat each role as an opportunity to acquire execution‑level capabilities, use generative AI to deepen scientific judgment, and continuously assess and market...
The Brave New World of Radiotherapeutics
Radiotherapeutics have moved from niche concepts to a burgeoning oncology platform, driven by unmet treatment gaps and the commercial breakthrough of Novartis' Pluvicto. Early data show Actinium‑225 delivering 45‑50% response rates in heavily pre‑treated prostate cancer, while Bayer's Xofigo adds...
After Missing Kezar Buyout in 2024, Tang Returns as CEO of Aurinia With $50M Offer
Kevin Tang, newly installed CEO of Aurinia Pharmaceuticals, has revived his bid for Kezar Life Sciences with a $50 million offer of $6.95 per share, roughly matching Kezar’s $47 million market cap. The proposal follows Tang’s earlier, unsuccessful $1.10‑per‑share attempt made through...
Takeda Restructuring Could Push More Than 600 US Staffers Out of Jobs
Takeda Pharmaceutical announced a U.S. restructuring that will affect roughly 634 employees, including 247 positions in its Cambridge, Massachusetts site. The plan aims to generate savings of over 200 billion yen (about $1.25 billion) by fiscal year 2028, funding upcoming product launches...
Kardigan Blood Pressure Drug Proves Hypothesis Despite Split Phase 2 Readout
Kardigan reported that its experimental hypertension drug tonlamarsen achieved a 67% average reduction in the angiotensinogen biomarker after five monthly doses, confirming target engagement. However, the Phase 2 trial showed no statistically significant difference in office systolic blood pressure between the...
Biogen Bounces Back With FDA Nod for High-Dose Spinal Muscular Atrophy Drug
The FDA approved a high‑dose formulation of Biogen’s SMA drug Spinraza, cutting the loading phase from four to two injections and adding a four‑month maintenance schedule. The new regimen, backed by the DEVOTE study, showed significant motor‑skill gains versus sham...